Aktuelle smitsomme sygdomme

This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 21-27 May 2023 May 2023 and includes updates on COVID-19, influenza, Marburg virus disease, poliomyelitis, extensively drug-resistant Pseudomonas aeruginosa, and suspected fungal meningitis.

This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 21-27 May 2023 May 2023 and includes updates on COVID-19, influenza, Marburg virus disease, poliomyelitis, extensively drug-resistant Pseudomonas aeruginosa, and suspected fungal meningitis.

BackgroundAntimicrobial resistance (AMR) is of public health concern worldwide. AimWe aimed to summarise the German AMR situation for clinicians and microbiologists. MethodsWe conducted a systematic review and meta-analysis of 60 published studies and data from the German Antibiotic-Resistance-Surveillance (ARS). Primary outcomes were AMR proportions in bacterial isolates from infected patients in Germany (2016–2021) and the case fatality rates (2010–2021). Random and fixed (common) effect models were used to calculate pooled proportions and pooled case fatality odds ratios, respectively. ResultsThe pooled proportion of meticillin resistance in Staphylococcus aureus infections (MRSA) was 7.9% with a declining trend between 2014 and 2020 (odds ratio (OR) = 0.89; 95% CI: 0.886–0.891; p 

This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 19-25 March 2023 and includes updates on Marburg virus disease, iatrogenic botulism, COVID-19, Influenza, Group A streptococcal infection, cholera, poliomyelitis, measles, and extensively drug-resistant Pseudomonas aeruginosa.

P. aeruginosa -- United StatesFederal inspectors found dozens of issues at an eye drops manufacturer now linked to a fatal outbreak of drug-resistant bacteria, inspection records released by the Food and Drug Administration show, ranging from dirty equipment and clothing to missing safeguards and procedures.The FDA's findings were detailed in citations issued to Indian manufacturer Global Pharma Healthcare Pvt Ltd after an inspection from 20 Feb through 2 Mar 2023. This appears to have been the company's 1st visit from…

This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 19-25 March 2023 and includes updates on Marburg virus disease, iatrogenic botulism, COVID-19, Influenza, Group A streptococcal infection, cholera, poliomyelitis, measles, and extensively drug-resistant Pseudomonas aeruginosa.

P. aeruginosa -- United States'As of 14 Mar 2023, CDC, in partnership with state and local health departments, identified 68 patients in 16 states (CA, CO, CT, FL, IL, NC, NJ, NM, NY, NV, PA, SD, TX, UT, WA, WI) with VIM-GES-CRPA, a rare strain of extensively drug-resistant _P. aeruginosa_. Thirty-seven patients were linked to 4 healthcare facility clusters. One person has died and there have been 8 reports of vision loss and 4 reports of enucleation (surgical removal of eyeball). Dates of specimen collection were from May…

P. aeruginosa -- United StatesThe Food and Drug Administration (FDA) has warned against using 'Artificial Tears' eye drops produced by a Tamil Nadu-based firm after an outbreak of drug-resistant infections was linked to the drug in the USA. This is the 3rd such controversy involving an Indian pharma company.Another controversy has hit India's pharmaceutical industry as the United States warned that an eye drop manufactured by a Tamil Nadu-based firm has caused an outbreak of the drug-resistant bacterium _Pseudomonas…

P. aeruginosa -- United StatesPatients should stop using EzriCare Artificial Tears pending additional information and guidance from CDC and FDA. If patients were advised to use EzriCare Artificial Tears by their healthcare provider, they should follow up with their healthcare provider for recommendations about alternative treatment options. Patients who have used EzriCare preservative-free artificial tears and who have signs or symptoms of an eye infection should seek medical care immediately. At this time, there is no…

P. aeruginosa -- United StatesOne person has died and at least 3 others are left with permanent vision loss because of a bacterial infection possibly linked to a brand of over-the-counter eyedrops, according to the Centers for Disease Control and Prevention (CDC). A majority of those affected reported using preservative-free EzriCare Artificial Tears before becoming ill, CDC reported in a statement dated 20 Jan 2023. While the infections have not been definitively traced to the eyedrops, CDC recommended that 'patients…

Background

Bloodstream infections (BSI) cause substantial morbidity and mortality.

Aim

We explored the role of causative pathogens and patient characteristics on the outcome of community-acquired (CA) and healthcare-associated (HA) BSI, with particular interest in early death.

Methods

We used national register data to identify all BSI in Finland during 2004–18. We determined the origin of BSI, patients´ underlying comorbidities and deaths within 2 or 30 days from specimen collection. A time-dependent Cox model was applied to evaluate the impact of patient characteristics and causative pathogens on the hazard for death at different time points.

Results

A total of 173,715 BSI were identified; 22,474 (12.9%) were fatal within 30 days and, of these, 6,392 (28.4%) occurred within 2 days (7.9 deaths/100,000 population). The 2-day case fatality rate of HA-BSI was higher than that of CA-BSI (5.4% vs 3.0%). Patients who died within 2 days were older than those alive on day 3 (76 vs 70 years) and had more severe comorbidities. Compared with other BSI, infections leading to death within 2 days were more often polymicrobial (11.8% vs 6.3%) and caused by Pseudomonas aeruginosa (6.2% vs 2.0%), fungi (2.9% vs 1.4%) and multidrug-resistant (MDR) pathogens (2.2% vs 1.8%), which were also predictors of death within 2 days in the model.

Conclusions

Overrepresentation of polymicrobial, fungal, P. aeruginosa and MDR aetiology among BSI leading to early death is challenging concerning the initial antimicrobial treatment. Our findings highlight the need for active prevention and prompt recognition of BSI and appropriate antimicrobial treatment.…

Hospital-Related Infection -- Norway…